Cucurbitacin D

Cucurbitacin D

SCHEMBL230654

CC(C)(O)/C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C[C@H](O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGAL P20701 3/20 1.00
SMN1; SMN2 Q16637 2/20 0.82
HIF1A Q16665 2/20 0.82
IGF2BP1 Q9NZI8 2/20 0.82
NPC1 O15118 2/20 0.82
RAB9A P51151 2/20 0.82
LMNA P02545 1/20 0.82
MAPT P10636 1/20 0.82
STAT3 P40763 1/20 0.82
HTT P42858 1/20 0.82
ATM Q13315 1/20 0.82
PAX8 Q06710 2/20 0.68
CYP3A4 P08684 1/20 0.68
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.47
ACHE P22303 2/20 0.45
TYR P14679 1/20 0.40
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cucurbitacin D SCHEMBL8166627 1.00 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Cucurbitacin D SCHEMBL20121444 1.00 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
SCHEMBL10307568 0.95 ITGAL (0.90) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
SCHEMBL21650384 0.92 ITGAL (0.86) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Amarin SCHEMBL17531553 0.90 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Amarin SCHEMBL19186443 0.90 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Cucurbitacin B SCHEMBL29602393 0.90 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Amarin SCHEMBL22433345 0.90 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Amarin SCHEMBL18177462 0.90 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1
Amarin SCHEMBL13668120 0.90 ITGAL (1.00) ITGALSMN1; SMN2HIF1AIGF2BP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024162488-A1 PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN 주식회사 재인알앤피 2024-08-08 WO claimed
CN-116381117-A Method for constructing graph of snakegourd, allium macrostemon and pinellia ternate Shang Zhiwen and measuring content of index components 澳门科技大学 2023-07-04 CN claimed
CN-116124958-A Method for constructing fingerprint spectrum of medicinal material of snakegourd fruit and measuring content of index components of snakegourd fruit 澳门科技大学 2023-05-16 CN claimed
CN-114681371-A Trichosanthes and bitter apricot seed compound extract, preparation method thereof and mask prepared from same 上海小方制药股份有限公司 2022-07-01 CN claimed
CN-114681375-A Refined extract of snakegourd fruit and bitter almond and preparation method thereof 上海小方制药股份有限公司 2022-07-01 CN claimed
CN-110590892-B Triterpene compound with anti-tumor activity separated from waste fructus Trichosanthis pulp and its application 南京中医药大学 2021-06-22 CN claimed
EP-2083828-B1 A STANDARDISED EXTRACT AND ITS USE IN THE MANUFACTURE OF A MEDICAMENT BOTANIC CENTURY BEIJING CO LTD (CN) 2020-01-29 EP claimed
CN-110041392-A A kind of preparation method of cucurbitacin D 浙江工业大学 2019-07-23 CN claimed
CN-108659087-A A kind of extraction process of cucurbitacin D 湖州展舒生物科技有限公司 2018-10-16 CN claimed
US-10076527-B2 Standardized extract and its use in the manufacture of a medicament BOTANIC CENTURY (BEIJING) CO., LTD. (CN) 2018-09-18 US claimed
WO-2007138239-A1 CUCURBITACINE ANALOGS OR AN EXTRACT FROM TRICHOSANTHES FOR TREATING ANEMIA ULTRA BIOTECH LIMITED (GB) 2007-12-06 WO claimed
WO-2007130523-A2 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIV INFECTION GEORGE MASON INTELLECTUAL PROPERTIES, INC. (US) 2007-11-15 WO claimed
CN-1919339-A Cucurbitacin nano preparation comprising protein, preparation method and use thereof MEDICINE SUBJECT UNIVERSITY OF (CN) 2007-02-28 CN claimed
CN-1883484-A Novel pharmacological use of cucurbitacine UNIV SHENYANG PHARMACEUTICAL (CN) 2006-12-27 CN claimed
US-20060246161-A1 METHOD OF MAKING MEDICAMENT FOR TREATING ANEMIA ULTRA BIOTECH LIMITED (GB) 2006-11-02 US claimed
WO-2005022167-A2 COMPOUNDS THAT ACT TO MODULATE INSECT GROWTH AND METHODS AND SYSTEMS FOR IDENTIFYING SUCH COMPOUNDS THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) 2005-03-10 WO claimed
US-20050049230-A1 Compounds that act to modulate insect growth and methods and systems for identifying such compounds UNIVERSITY OF NORTH CAROLINA AT GREENSBORO, THE 2005-03-03 US claimed
US-20040138189-A1 Moderation of intracellular signals; antitumor agents; drug screening; administering cucurbitacin compound NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-07-15 US claimed
WO-2002078617-A2 MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS UNIVERSITY OF SOUTH FLORIDA (US) 2002-10-10 WO claimed
US-5925356-A Method of isolating cucurbitacin JP MORGAN CHASE BANK 1999-07-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049230-A1 Compounds that act to modulate insect growth and methods and systems for identifying such compounds FXR2, FXR1, NR1H2 ITGAL 3967/4885SMN1; SMN2 4482/4885HIF1A 4698/4885
US-20060246161-A1 METHOD OF MAKING MEDICAMENT FOR TREATING ANEMIA HBG1, HBG2, HBZ ITGAL 1266/4885SMN1; SMN2 2007/4885HIF1A 69/4885
US-20040138189-A1 Moderation of intracellular signals; antitumor agents; drug screening; administering cucurbitacin compound STAT3, STAT1, JAK2 ITGAL 4681/4885SMN1; SMN2 4227/4885HIF1A 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.